NASDAQ:TNXP Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis $45.52 +0.77 (+1.72%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$46.11 +0.59 (+1.30%) As of 06:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tonix Pharmaceuticals Stock (NASDAQ:TNXP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tonix Pharmaceuticals alerts:Sign Up Key Stats Today's Range$43.50▼$46.0050-Day Range$23.10▼$47.1952-Week Range$6.76▼$130.00Volume1.73 million shsAverage Volume1.02 million shsMarket Capitalization$334.89 millionP/E RatioN/ADividend YieldN/APrice Target$70.00Consensus RatingBuy Company Overview Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Read More Tonix Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreTNXP MarketRank™: Tonix Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 590th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTonix Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Tonix Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($1,762.50) to ($541.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTonix Pharmaceuticals has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tonix Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.46% of the float of Tonix Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTonix Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tonix Pharmaceuticals has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTonix Pharmaceuticals does not currently pay a dividend.Dividend GrowthTonix Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.46% of the float of Tonix Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTonix Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tonix Pharmaceuticals has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 58 people have searched for TNXP on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat FollowsOnly 38 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -32% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,200.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.03% of the stock of Tonix Pharmaceuticals is held by insiders.Percentage Held by Institutions82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tonix Pharmaceuticals' insider trading history. Receive TNXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TNXP Stock News HeadlinesTonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by FibromyalgiaJuly 21 at 7:00 AM | globenewswire.comTonix Pharma Plans Sales Force for TNX-102 SLJuly 16, 2025 | tipranks.comBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, who called Bitcoin’s breakout to $100K nearly to the day, says a lesser-known coin could be even bigger. It’s faster, cheaper, and backed by Google, Visa, and top VCs with over $200 million already invested. | Weiss Ratings (Ad)Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine ResultsJuly 10, 2025 | msn.comTonix up after peer reviewed data for pain therapy and new data for mpox vaccineJuly 10, 2025 | msn.comTonix Pharmaceuticals (TNXP) Surges 10% on Phase 3 Data ReleaseJuly 10, 2025 | gurufocus.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10, 2025 | gurufocus.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10, 2025 | gurufocus.comSee More Headlines TNXP Stock Analysis - Frequently Asked Questions How have TNXP shares performed this year? Tonix Pharmaceuticals' stock was trading at $32.98 at the start of the year. Since then, TNXP shares have increased by 38.0% and is now trading at $45.52. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings results on Monday, May, 12th. The company reported ($2.84) EPS for the quarter, topping the consensus estimate of ($3.23) by $0.39. The firm had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative trailing twelve-month return on equity of 120.96%. When did Tonix Pharmaceuticals' stock split? Tonix Pharmaceuticals shares reverse split on Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tonix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include Meta Platforms (META), Digital Turbine (APPS), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). Company Calendar Last Earnings5/12/2025Today7/24/2025Next Earnings (Estimated)8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNXP CIK1430306 Webwww.tonixpharma.com Phone(862) 799-8599Fax212-923-5700Employees50Year FoundedN/APrice Target and Rating Average Price Target for Tonix Pharmaceuticals$70.00 High Price Target$70.00 Low Price Target$70.00 Potential Upside/Downside+53.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1,963.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.04 million Net Margins-1,313.87% Pretax Margin-1,313.87% Return on Equity-120.96% Return on Assets-101.28% Debt Debt-to-Equity RatioN/A Current Ratio12.31 Quick Ratio11.64 Sales & Book Value Annual Sales$10.04 million Price / Sales33.35 Cash FlowN/A Price / Cash FlowN/A Book Value$31.82 per share Price / Book1.43Miscellaneous Outstanding Shares7,357,000Free Float7,355,000Market Cap$334.89 million OptionableNot Optionable Beta2.05 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:TNXP) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredI was wrong about TrumpAddiction. Crime. Corruption. One devastating lie may be fueling it all. A new exposé reveals the hidden ca...Porter & Company | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.